HomeCompareMSGCF vs MRK

MSGCF vs MRK: Dividend Comparison 2026

MSGCF yields 21505.38% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSGCF wins by $107882141815352868864.00M in total portfolio value
10 years
MSGCF
MSGCF
● Live price
21505.38%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107882141815352868864.00M
Annual income
$106,904,261,402,781,760,000,000,000.00
Full MSGCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MSGCF vs MRK

📍 MSGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSGCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSGCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSGCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSGCF
Annual income on $10K today (after 15% tax)
$1,827,956.99/yr
After 10yr DRIP, annual income (after tax)
$90,868,622,192,364,500,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MSGCF beats the other by $90,868,622,192,364,500,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSGCF + MRK for your $10,000?

MSGCF: 50%MRK: 50%
100% MRK50/50100% MSGCF
Portfolio after 10yr
$53941070907676434432.00M
Annual income
$53,452,130,701,390,880,000,000,000.00/yr
Blended yield
99.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MSGCF
No analyst data
Altman Z
-7.7
Piotroski
1/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSGCF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSGCFMRK
Forward yield21505.38%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$107882141815352868864.00M$57.7K
Annual income after 10y$106,904,261,402,781,760,000,000,000.00$10,113.78
Total dividends collected$107817657762195783680.00M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSGCF vs MRK ($10,000, DRIP)

YearMSGCF PortfolioMSGCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,161,238$2,150,537.63$11,213$373.04+$2.15MMSGCF
2$436,688,493$434,375,969.13$12,667$512.06+$436.68MMSGCF
3$82,493,201,274$82,025,944,586.28$14,439$708.14+$82493.19MMSGCF
4$14,569,778,490,541$14,481,510,765,177.32$16,640$988.16+$14569778.47MMSGCF
5$2,405,958,319,119,619$2,390,368,656,134,740.00$19,432$1,394.07+$2405958319.10MMSGCF
6$371,480,833,454,370,940$368,906,458,052,912,960.00$23,057$1,992.90+$371480833454.35MMSGCF
7$53,630,466,141,085,860,000$53,232,981,649,289,680,000.00$27,889$2,894.79+$53630466141085.84MMSGCF
8$7,239,827,382,966,988,000,000$7,182,442,784,196,026,000,000.00$34,518$4,286.29+$7239827382966988.00MMSGCF
9$913,906,927,636,562,000,000,000$906,160,312,336,787,400,000,000.00$43,912$6,494.35+$913906927636562048.00MMSGCF
10$107,882,141,815,352,870,000,000,000$106,904,261,402,781,760,000,000,000.00$57,714$10,113.78+$107882141815352868864.00MMSGCF

MSGCF vs MRK: Complete Analysis 2026

MSGCFStock

MAS Gold Corp., an exploration stage company, engages in the exploration, evaluation, and development of mineral properties in Canada. It primarily explores for gold deposits. The company holds 4 mineral properties covering an area of 33,583 hectares located in the La Ronge gold belt. It principally holds interests in the Greywacke, Preview-North, Henry Lake, and Elizabeth Lake properties located in La Ronge gold belt, Saskatchewan. The company was formerly known as Masuparia Gold Corporation and changed its name to MAS Gold Corp. in April 2018. MAS Gold Corp. was incorporated in 1981 and is based in Saskatoon, Canada.

Full MSGCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MSGCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSGCF vs SCHDMSGCF vs JEPIMSGCF vs OMSGCF vs KOMSGCF vs MAINMSGCF vs JNJMSGCF vs ABBVMSGCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.